Fatigue and functioning-associated quality of life (QOL) scores
as scaled by EORTC QOL-C30 significantly improved following
Theracurmin administration (Table 2). In
five patients, the fatigue score improved by >20, which was interpreted as a significant and
clinically relevant change [13]. Improved QOL has been demonstrated
to contribute to better outcomes in cancer patients;
therefore, we speculate that Theracurmin may prolong the overall
survival of patients with pancreatic cancer through QOL improve-
ments. A randomized phase II trial using highly bioavailable
curcumin (Theracurmin) in patients with unresectable advanced
pancreatic cancer (UMIN000010326) is now underway to verify
this hypothesis.